Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
10 participants
INTERVENTIONAL
2025-07-01
2029-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Robotic Flexible Ureteroscopy Versus Standard Flexible Ureteroscopy for Renal Stones
NCT06660914
Flexible Ureteroscopy With Tip-bendable Suction Ureteral Access Sheath Versus Mini-Percutaneous Nephrolithotomy for Treatment of 2-3cm Renal Stones
NCT06526390
A Multicenter Prospective Research on the Treatment of Low Pole Renal Calculus by Flexible Ureteroscope
NCT03105206
Comparison of the Efficacy of Flexible Ureteroscope and Percutaneous Nephroscopic Surgery in the Treatment of 2-4cm Kidney Stones
NCT06507176
Suctioning Flexible Ureteroscopy With Intelligent Control of Renal Pelvic Pressure
NCT02734914
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study is intended to identify patients who have undergone kidney-sparing surgery for upper tract urothelial carcinoma with need of surveillance of the upper urinary tract.
Prior to procedure, mid-stream or catheterised urine samples will be collected two weeks beforehand. To ensure a sterile urinary tract, asymptomatic bacteriuria will be treated with antibiotics tailored to the urine culture results, or with broad spectrum antibiotics. Anti-platelet or anticoagulation medications will be discontinued in accordance with local guidelines prior to the operation.
Procedures will be conducted by experienced urology specialists.The procedure will commence with the patient in a supine position, followed by the administration of transurethral lidocaine jelly five minutes prior to the procedure - either in room temperature or chilled preparation. Additional intravenous sedative medication prior to the endoscopic examination will be optional.
Initially, a flexible cystoscope will be introduced to examine the bladder and ureteric orifices, and a lower tract surveillance will be performed. In cases without a pre- existing ureteric double J stent, the ureteric orifice may be cannulated with a guidewire, followed by the introduction of a flexible ureteroscope, either alongside or railroading the guidewire.
The decision to use a guidewire in cases with tight ureteric orifices will be made by the operating urologist. If a ureteric double J stent is in situ, it will be retrieved using foreign body forceps with a flexible cystoscope, and a guidewire will be used for the stent exchange, then the flexible ureteroscope will be introduced alongside or railroading the guidewire.
The choice of ureteroscope will be left to the operating urologist's discretion. The procedure will either be performed with a reusable or a disposable fURS. The fURS will be inserted to the renal pelvis by direct vision. A complete renoscopy for the tip of the fURS deflecting to the different calyces will be performed. After renoscopy, the fURS will be carefully and slowly withdrawn. Saline irrigation through the instrumental channel will continually take place to ensure visibility of the lumen. During withdrawal, the ureter will be inspected, until the fURS is retrieved through the ureteric orifice. During renoscopic and ureteroscopic examination, findings will be documents in a pre-specified electornic form. Any suspicious mucosal lesion may be biopsied, subject to the operating urologist's judgment. A circulating nurse will monitor the patient's blood pressure, pulse, and pulse oximetry throughout the procedure. Should the patient experience intolerable discomfort or significant derangement in vital signs, the procedure will be immediately ceased.
Post-procedure, patients will be observed in the observation are of the ambulatory centre. Vital signs including blood pressure, pulse, oxygen saturation, and temperature will be monitored. Patients who do not require an indwelling urinary catheter will be encouraged to void, and their post-void residual urine volume will be recorded. Discharge from the ambulatory unit will be authorized only if the patient's vital signs remain stable and they demonstrate adequate voiding.
Upon discharge, all baseline characteristics and peri-procedural complications will be meticulously recorded in a designated electronic form. Complications will be graded using the Clavien-Dindo classification, and electronic records will be reviewed for up to 30 days post-procedure to document any instances of hospital attendance and the reasons thereof. i.e., ureterorenoscopy under anesthesia in an operating theatre. However, should any suspected ureteric injury or avulsion occur-a risk also inherent in standard procedures-the ureterorenoscopy will be halted, a double J stent will be placed via the guidewire, and the patient will be admitted to an inpatient ward for further monitoring and management.
The participants will be continually monitored if they suffer from any adverse event, till resolution of the event. All patients who experience an adverse event (AE) will be evaluated at appropriate time intervals until the event resolves or stabilizes. At the conclusion of the study, the investigator will assess unresolved AE and determine if additional follow-up is warranted based on clinical assessment.
Collection of Serious adverse event (SAE) information will begin at the time the patient signs the informed consent and continue through screen failure, end of study follow-up, or safety follow-up if the condition is not resolved or stabilized All SAE must be followed with appropriate medical management until resolved or until progression has been stabilized.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ambulatory flexible ureterorenoscopy
Ambulatory flexible ureterorenoscopy
Ambulatory flexible ureterorenoscopy (experimental)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ambulatory flexible ureterorenoscopy
Ambulatory flexible ureterorenoscopy (experimental)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Capable of giving informed consent
3. Having undergone an kidney-sparing surgery (endoscopic operation or segmental ureterectomy)
Exclusion Criteria
2. On anticoagulation or anti-platelet medication with contraindications for cessation prior to the procedure
3. Structural abnormalities in the upper urinary tract on the intended side of examination
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese University of Hong Kong
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wong, Ho Ming Chris
Resident Doctor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Prince of Wales Hospital
Hong Kong, , Hong Kong
The Chinese University of Hong Kong
Hong Kong, , Hong Kong
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Chris Wong
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Jain K, Blachman-Braun R, Jain E, Eng A, Peters B, Patel P. Ureteroscopy under conscious sedation: A proof-of-concept study. Can Urol Assoc J. 2022 Sep;16(9):E461-E467. doi: 10.5489/cuaj.7750.
Peng Y, Wang L, Jin J, Jiang Y, Xu Q, Yang L, Liu J. Flexible ureteroscopy under local anesthesia for stone management: initial exploration and two-year experience. Postgrad Med. 2023 Sep;135(7):755-762. doi: 10.1080/00325481.2023.2265991. Epub 2023 Oct 24.
Villa L, Cloutier J, Letendre J, Ploumidis A, Salonia A, Cornu JN, Montorsi F, Traxer O. Early repeated ureteroscopy within 6-8 weeks after a primary endoscopic treatment in patients with upper tract urothelial cell carcinoma: preliminary findings. World J Urol. 2016 Sep;34(9):1201-6. doi: 10.1007/s00345-015-1753-7. Epub 2015 Dec 23.
Cybulski PA, Joo H, Honey RJ. Ureteroscopy: anesthetic considerations. Urol Clin North Am. 2004 Feb;31(1):43-7, viii. doi: 10.1016/S0094-0143(03)00087-9.
Zganjar AJ, Thiel DD, Lyon TD. Diagnosis, workup, and risk stratification of upper tract urothelial carcinoma. Transl Androl Urol. 2023 Sep 30;12(9):1456-1468. doi: 10.21037/tau-23-45. Epub 2023 Aug 4.
Pandolfo SD, Cilio S, Aveta A, Wu Z, Cerrato C, Napolitano L, Lasorsa F, Lucarelli G, Verze P, Siracusano S, Quattrone C, Ferro M, Bologna E, Campi R, Del Giudice F, Bertolo R, Amparore D, Palumbo S, Manfredi C, Autorino R. Upper Tract Urothelial Cancer: Guideline of Guidelines. Cancers (Basel). 2024 Mar 11;16(6):1115. doi: 10.3390/cancers16061115.
Babjuk M, Burger M, Capoun O, Cohen D, Comperat EM, Dominguez Escrig JL, Gontero P, Liedberg F, Masson-Lecomte A, Mostafid AH, Palou J, van Rhijn BWG, Roupret M, Shariat SF, Seisen T, Soukup V, Sylvester RJ. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2022 Jan;81(1):75-94. doi: 10.1016/j.eururo.2021.08.010. Epub 2021 Sep 10.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB/REC 2024.432
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.